Healthcare
Live Price
Offline$129.46
+0.14% today
Window Change
+0.83%
Window
Jun 23, 2025 → Jul 18, 2025
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 19 bars · Jun 23, 2025 → Jul 18, 2025
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Blueprint Medicines Corporation (BPMC) is a Healthcare stock with a market cap of $8.36B. The stock last traded around $129.46 and up 0.8% across the available one-year price window (Jun 23, 2025 → Jul 18, 2025). Baseline metrics include revenue growth of +104.0%, EPS growth of +87.2%, a dividend yield of 0.0%. What stands out right now is revenue +104.0%, EPS +87.2%, free cash flow +56.5% with operating margin -27.8% and ROIC -8.2%. Valuation already assumes a fairly strong business story at price/sales 28.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines BPMC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BPMC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BPMC Max Drawdown
-0.23%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BPMC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$793.7M
+340.8% YoY
FY Net Income
$313.9M
+148.7% YoY
Free Cash Flow
$383.9M
+168.6% YoY
Revenue Growth
+104.0%
EPS Growth
+87.2%
Gross Margin
96.5%
Net Margin
-16.7%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 509M | 249M | 204M | 180M | 794M |
| Gross Profit | 489M | 237M | 186M | 162M | 793M |
| Operating Income | -212M | -486M | -549M | -648M | 302M |
| EBITDA | 19M | -470M | -515M | -628M | 309M |
| Net Income | -67M | -507M | -558M | -644M | 314M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 102M | 71M | 120M | 210M | 685M |
| Total Assets | 1.2B | 1.0B | 1.3B | 1.3B | 1.7B |
| Total Liabilities | 881M | 919M | 835M | 281M | 248M |
| Shareholder Equity | 299M | 131M | 515M | 971M | 1.5B |
| Total Debt | 469M | 774M | 242M | 111M | 90M |
| Net Debt | 367M | 703M | 123M | -99M | -595M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
387M
+229.6% YoY
Capital Expenditures
3M
+98.8% YoY
Free Cash Flow
384M
+168.6% YoY
Key ratios
Gross Margin
96.5%
Operating Margin
-27.8%
Net Margin
-16.7%
ROE
-15.4%
Debt / Equity
0.36x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.